Pliant Therapeutics

PLRX · NASDAQ

$0.9124+$0.0137 (+1.52%)TodayMarket closed · Oct 20, 4:27 PM ET

Prev close $0.8987

PLRX analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.

Strong buy0
Buy1
Hold2
Underperform0
Sell0

12-month price target · 3 analysts

Average $2.04 (+123.6% upside)

Low: $2.02
Now: $0.9124
High: $2.10

Upgrades and downgrades

The latest rating actions, newest first

PLRX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Canaccord Genuity	Mar 13, 2026	Maintains	Hold	$4.00 → $3.00	44%
Piper Sandler	Mar 12, 2026	Maintains	Overweight	$4.00 → $3.00	37%
RBC Capital	Nov 7, 2025	Maintains	Sector Perform	$3.00 → $2.00	44%

The case for and against

Updated Sep 1, 2026

Bull case

Pliant Therapeutics is in a strong financial position with a focus on developing and commercializing novel integrin-based treatments for solid tumors through their proprietary drug discovery platform. The company's lead product candidate, PLN-101095, has shown promising results in early clinical trials and they have a well-diversified pipeline of integrin-based programs across multiple disease areas. With ongoing trials and potential for combination therapy with other drugs like pembrolizumab, Pliant Therapeutics has a high probability of success, making it a stock with positive outlook for investors.

Bear case

Pliant Therapeutics is facing potential challenges with regards to its lead product candidate, PLN-101095, as the company awaits proof-of-concept clinical data. This could impact its ability to generate revenue and raise concerns about the sustainability of its pipeline. This is reflected in the decrease in its price target from $4 to $3, driven by the company's updated cash position and share counts.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.